PetMedix
Job Description PetMedix , based in Cambridge, UK, is a biotech company making antibody therapeutics for companion animals (dogs and cats).
We are seeking a self - motivated, energetic, and highly detail - oriented research associate with a proven background in cell culture , ideally ES cell culture. This position will apply high - throughput genomic engineering and genotyping of modified murine ES cells to support the development of PetMedix’s proprietary antibody discovery platform . Responsibilities will include, but are not limited to, the following:
• Genetic engineering and culture of mouse ES cell lines • Quality control, maintenance and cryopreservation of mouse ES cell lines • Genotyping of mouse ES cells • Preparation of mouse ES cells for blastocyst microinjection • Support in technology development • Maint enance of an accurate electronic notebook in a timely manner • Effective communicat ion of results and findings Requirements & Education Bachelor’s degree or equivalent. Proven work experience using aseptic techniques in cell culture . Experience in PCR, gel electrophoresis and ideally sequencing. Solid knowledge of cellular / molecular biology and understanding of transgenic s . Excellent organizational, communication and record - keeping skills . Strong motivation and team spirit.
Terms This is full - time role with a competitive salary in line with experience and other benefits such as company share options, private pension plan and health insurance.
Contact If you would like to become a member of our team, please send your application to info@petmedix.co.uk with a covering letter and your CV.
About PetMedix PetMedix is a Cambridge, UK based early stage pharmaceutical company with global ambitions to become the world leader in innovative antibody - based therapeutics for the companion animal market. We will deliver the first transgenic mouse platform capable of producing therapeutic - quality antibody drugs fully adopted to the target companion <::> animal. The plat form is species - agnostic and our initial focus will be to develop the Ky9 mouse model for creating therapeutic antibodies first for dogs, and then equivalent models for cats and horses.
